These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. Uncini A; Eleopra R; Onofrj M J Neurol Neurosurg Psychiatry; 2015 May; 86(5):490-5. PubMed ID: 25168395 [TBL] [Abstract][Full Text] [Related]
4. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
5. Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion. Bove F; Luigetti M; Gallicchio L; Recchia V; Petruzzellis A; Di Iorio R; Tamma F; Fasano A Neurol Sci; 2017 Oct; 38(10):1869-1872. PubMed ID: 28642996 [TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Merola A; Zibetti M; Rizzone MG; Troiano M; Artusi CA; Angrisano S; Cocito D; Lopiano L Acta Neurol Scand; 2014 Jan; 129(1):e1-5. PubMed ID: 23834498 [TBL] [Abstract][Full Text] [Related]
7. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085 [TBL] [Abstract][Full Text] [Related]
8. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease. Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489 [TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Müller T; van Laar T; Cornblath DR; Odin P; Klostermann F; Grandas FJ; Ebersbach G; Urban PP; Valldeoriola F; Antonini A Parkinsonism Relat Disord; 2013 May; 19(5):501-7 ; discussion 501. PubMed ID: 23453891 [TBL] [Abstract][Full Text] [Related]
10. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience. Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531 [TBL] [Abstract][Full Text] [Related]
12. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410 [TBL] [Abstract][Full Text] [Related]
13. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838 [TBL] [Abstract][Full Text] [Related]
14. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635 [TBL] [Abstract][Full Text] [Related]
16. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease. Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942 [TBL] [Abstract][Full Text] [Related]
17. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907 [TBL] [Abstract][Full Text] [Related]
18. Acute/subacutae demyelinating polyneuropathy in Parkinson's Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report. Piekarski R; Roszmann A; Dulski J; Sławek J Neurol Neurochir Pol; 2023; 57(2):169-176. PubMed ID: 36628506 [TBL] [Abstract][Full Text] [Related]